Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients

References

• Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459–1466
   PubMed Web of Science ®Google Scholar
• Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19: 801–808
   PubMed Web of Science ®Google Scholar
• Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003; 101: 3365–3372
   PubMed Web of Science ®Google Scholar
• Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475–482
   PubMed Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527–1533
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827–833
   PubMed Web of Science ®Google Scholar
• Mossad SB, Longworth DL, Goormastic M, Serkey JM, Keys TF, Bolwell BJ. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996; 18: 265–271
   PubMed Web of Science ®Google Scholar
• Barton T, Collis T, Stadtmauer E, Schuster M. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 2001; 32: 391–395
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Olivieri A, et al. Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant 1999; 24: 1079–1087
   PubMed Web of Science ®Google Scholar
• Montesinos J, Sola C, Maroto P, et al. Fungal infections in patients with solid tumors treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Eur J Clin Microbiol Infect Dis 2001; 20: 569–572
   Google Scholar
• Auner HW, Sill H, Mulabecirovic A, Linkesch W, Krause R. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann Hematol 2002; 81: 374–377
   PubMed Web of Science ®Google Scholar
• Jantunen E, Salonen J, Juvonen E, Koivunen E, Siitonen T, Lehtinen T, et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol 2004; 73: 174–178
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917
   PubMed Web of Science ®Google Scholar
• Liberti G, Pearce R, Taghipour G, Majolino I, Goldstone AH. Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: a case-controlled analysis of the EBMT Registry data. Lymphoma Working Party of the EBMT. Ann Oncol 1994; 5(Suppl 2)151–153
   Google Scholar
• D'Antonio D, Iacone A, Pierelli L, Bonfini T. Patterns of recovery phase infection after autologous blood progenitor cell transplantation in patients with malignancies. The Gruppo Italiano di Studio per la Manipolazione Cellulare in Ematologia. Eur J Clin Microbiol Infect Dis 1995; 14: 552–556
   Google Scholar
• Dykewicz CA. Hospital infection control in hematopoietic stem cell transplant recipients. Emerg Infect Dis 2001; 7: 263–267
   Google Scholar
• Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 2001; 33: 139–144
   PubMed Web of Science ®Google Scholar
• Dykewicz CA, Jaffe HA, Kaplan JE. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000; 6: 659–713
   Google Scholar
• Sullivan KM, Dykewicz CA, Longworth DL, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology. Am Soc Hematol Educ Program 2001; 0: 392–421
   Google Scholar
• Trifilio S, Verma A, Mehta J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 2004; 33: 735–739
   PubMed Web of Science ®Google Scholar
• Bow EJ. Invasive fungal infection in patients receiving intensive cytotoxic therapy for cancer. Br J Haematol 1998; 101(suppl 1)1–4
   Google Scholar
• Karabinis A, Hill C, Leclercq B, Tancrede C, Baume D, Andremont A. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988; 26: 429–432
   PubMed Web of Science ®Google Scholar
• Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicentre surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071–1079
   PubMed Web of Science ®Google Scholar
• Safdar A, Perlin DS, Armstrong D. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis 2002; 44: 11–16
   PubMed Web of Science ®Google Scholar
• Bodey GP. Fungal infections in the cancer patient. S Afr Med J 1977; 52: 1009–1015
   Google Scholar
• DeGregorio MW, Lee WMF, Linker CA, Jacobs RA, Ries CA. Fungal infections in patients with acute leukemia. Am J Med 1982; 73: 543–548
   PubMed Web of Science ®Google Scholar
• Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100: 345–351
   PubMed Web of Science ®Google Scholar
• Holding KJ, Dworkin MS, Wan PC, et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project. Clin Infect Dis 2000; 31: 1253–1257
   PubMed Web of Science ®Google Scholar
• Aisner J, Murillo J, Schimpff SC, Steere AC. Invasive aspergillosis in acute leukemia: correlation with nose cultures and antibiotic use. Ann Intern Med 1979; 90: 4–9
   PubMed Web of Science ®Google Scholar
• Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20: 1526–1530
   PubMed Web of Science ®Google Scholar
• Laverdiere M, Rotstein C, Bow EJ, et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. J Antimicrob Chemother 2000; 46: 1001–1008
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309–316
   PubMed Web of Science ®Google Scholar
• Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136: 834–844
   PubMed Web of Science ®Google Scholar
• Aisner J, Schimpff SC, Bennett JE, Young VM, Wiernik PH. Aspergillus infections in cancer patients. Association with fireproofing materials in a new hospital. JAMA 1976; 235: 411–412
   PubMed Web of Science ®Google Scholar
• Arnow PM, Andersen RL, Mainous PD, Smith EJ. Pumonary aspergillosis during hospital renovation. Am Rev Respir Dis 1978; 118: 49–53
   PubMed Web of Science ®Google Scholar
• Sarubbi FA, Jr, Kopf HB, Wilson MB, McGinnis MR, Rutala WA. Increased recovery of Aspergillus flavus from respiratory specimens during hospital construction. Am Rev Respir Dis 1982; 125: 33–38
   PubMed Web of Science ®Google Scholar
• Lentino JR, Rosenkranz MA, Michaels JA, Kurup VP, Rose HD, Rytel MW. Nosocomial aspergillosis: a retrospective review of airborne disease secondary to road construction and contaminated air conditioners. Am J Epidemiol 1982; 116: 430–437
   PubMed Web of Science ®Google Scholar
• Opal SM, Asp AA, Cannady PB, Morse PL, Burton LJ, Hammer PG. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis 1986; 153: 634–637
   PubMed Web of Science ®Google Scholar
• Sherertz RJ, Belani A, Kramer BS, Elfenbein GJ, Weiner RS, Sullivan ML, et al. Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med 1987; 83: 709–718
   PubMed Web of Science ®Google Scholar
• Gerson SL, Parker P, Jacobs MR, Creger R, Lazarus HM. Aspergillosis due to carpet contamination. Infect Control Hosp Epidemiol 1994; 15: 221–213
   Google Scholar
• Loo VG, Bertrand C, Dixon C, et al. Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit. Infect Control Hosp Epidemiol 1996; 17: 360–364
   PubMed Web of Science ®Google Scholar
• Cornet M, Levy V, Fleury L, et al. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol 1999; 20: 508–513
   PubMed Web of Science ®Google Scholar
• Thio CL, Smith D, Merz WG, et al. Refinements of environmental assessment during an outbreak investigation of invasive aspergillosis in a leukemia and bone marrow transplant unit. Infect Control Hosp Epidemiol 2000; 21: 18–23
   PubMed Web of Science ®Google Scholar
• Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001; 66: 257–262
   PubMed Web of Science ®Google Scholar
• Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995; 21: 361–369
   PubMed Web of Science ®Google Scholar
• Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12: 310–350
   PubMed Web of Science ®Google Scholar
• Burch PA, Karp JE, Merz WG, Kuhlman JE, Fishman EK. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987; 5: 1985–1993
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055–2061
   PubMed Web of Science ®Google Scholar
• Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99: 2726–2733
   Google Scholar
• Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97: 3380–3389
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Guthrie KA, et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10: 494–503
   PubMed Web of Science ®Google Scholar
• Latge JP. The pathobiology of Aspergillus fumigatus. Trends Microbiol 2001; 9: 382–389
   PubMed Web of Science ®Google Scholar
• Yates JW, Holland JF. A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients. Cancer 1973; 32: 1490–1498
   PubMed Web of Science ®Google Scholar
• Levine AS, Siegel SE, Schreiber AD, et al. Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in acute leukemia. N Engl J Med 1973; 288: 477–487
   PubMed Web of Science ®Google Scholar
• Schimpff SC, Greene WH, Young VM, et al. Infection prevention in acute nonlymphocytic leukemia – laminar air flow room reverse isolation with oral nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975; 82: 351–358
   PubMed Web of Science ®Google Scholar
• Dietrich M, Gaus W, Vossen J, van der Waaij D, Wendt F, International Antimicrobial Therapy Cooperative Project Group. EORTC. Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection: a prospective cooperative study of gnotobiotic care in acute leukemia patients. 1. Clinical results. Infection 1977; 5: 107–114
   Google Scholar
• Schimpff SC, Hahn DM, Brouillet MD, Young VM, Fortner CL, Wiernik PH. Comparison of basic infection prevention techniques, with standard room reverse isolation or with reverse isolation plus added air filtration. Leukemia Res 1978; 2: 231–240
   Google Scholar
• Rodriguez V, Bodey GP, Freireich EJ, et al. Randomized trial of protected environment-prophylactic antibiotics in 145 adults with acute leukemia. Medicine 1978; 57: 253–266
   PubMed Web of Science ®Google Scholar
• Buckner CD, Clift RA, Sanders JE, et al. Protective environment for marrow transplant recipients – a prospective study. Ann Intern Med 1978; 89: 893–901
   PubMed Web of Science ®Google Scholar
• Lohner D, Debusscher L, Prévost JM, Klastersky J. Comparative randomized study of protected environment plus oral antibiotics versus oral antibiotics alone in neutropenic patients. Cancer Treatment Reports 1979; 63: 363–368
   Google Scholar
• Nauseef WM, Maki DG. A study of the value of simple protective isolation in patients with granulocytopenia. N Engl J Med 1981; 304: 448–453
   PubMed Web of Science ®Google Scholar
• Valdivieso M, Cabanillas F, Keating M, et al. Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units. Am J Med 1984; 76: 405–412
   Google Scholar
• Navari RM, Buckner CD, Clift RA, et al. Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants. Am J Med 1984; 76: 564–572
   PubMed Web of Science ®Google Scholar
• Passweg JR, Rowlings PA, Atkinson KA, et al. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1998; 21: 1231–1238
   PubMed Web of Science ®Google Scholar
• Gotzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 1997; 314: 1238–1244
   PubMed Web of Science ®Google Scholar
• Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against infection in neutropenic patients – a meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89: 1611–1625
   PubMed Web of Science ®Google Scholar
• Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230–3246
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4615–4626
   PubMed Web of Science ®Google Scholar
• Castagnola E, Machetti M, Bucci B, Viscoli C. Antifungal prophylaxis with azole derivatives. Clin Microbiol Infect 2004; 10(Suppl 1)86–95
   Google Scholar
• Berenguer J, Ali NM, Allende MC, et al. Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 1994; 38: 1303–1308
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443–451
   PubMed Web of Science ®Google Scholar
• Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De BK. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32(Suppl 1)103–108
   PubMed Web of Science ®Google Scholar
• Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165: 891–897
   PubMed Web of Science ®Google Scholar
• Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577–582
   PubMed Web of Science ®Google Scholar
• Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994; 97: 509–514
   PubMed Web of Science ®Google Scholar
• Kelsey SM, Goldman JM, McCann S, Newland AC, Scarffe JH, Oppenheim BA. Liposomal amphotercin B (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomized, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23: 163–168
   PubMed Web of Science ®Google Scholar
• van Burik J, Ratanatharathorn V, Lipton J, Miller C, Bunin N, Walsh TJ. Micafungin versus fluconazole for prophylaxis against invasive fungal infection during neutropenia in patients undergoing haematopoeitic stem cell transplant. Clin Infec Dis 2004; 39: 1407–1416
   PubMed Web of Science ®Google Scholar
• Hamza NS, Ghannoum MA, Lazarus HM. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2004; 34: 377–389
   PubMed Web of Science ®Google Scholar
• Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557–1559
   PubMed Web of Science ®Google Scholar
• McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043–2048
   PubMed Web of Science ®Google Scholar
• Wingard JR, Leather H. A new era of antifungal therapy. Biol Blood Marrow Transplant 2004; 10: 73–90
   PubMed Web of Science ®Google Scholar
• Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328–340
   PubMed Web of Science ®Google Scholar
• Bodey GP, Rodriguez V, Chang HY, et al. Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer 1978; 41: 1610–1622
   PubMed Web of Science ®Google Scholar
• Schmitz N, Bacigalupo A, Hasenclever D, et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995–1003
   PubMed Web of Science ®Google Scholar
• Vigorito AC, Azevedo WM, Marques JFC, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22: 1145–1151
   PubMed Web of Science ®Google Scholar
• Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol 2000; 18: 537–546
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181
   PubMed Web of Science ®Google Scholar
• Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525–1531
   PubMed Web of Science ®Google Scholar
• Jones GR, Konsler GK, Dunaway RP, Gold SH, Cooper HA, Wells RJ. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition. J Pediatr 1994; 124: 703–708
   PubMedGoogle Scholar
• Rackoff WR, Gonin R, Robinson C, Kreissman SG, Breitfeld PB. Predicting the risk of bacteremia in childen with fever and neutropenia. J Clin Oncol 1996; 14: 919–924
   PubMed Web of Science ®Google Scholar
• Klaassen RJ, Goodman TR, Pham B, Doyle JJ. ‘Low-risk’ prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18: 1012–1019
   PubMed Web of Science ®Google Scholar
• Baorto EP, Aquino VM, Mullen CA, Buchanan GR, DeBaun MR. Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer 2001; 92: 909–913
   PubMed Web of Science ®Google Scholar
• Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol 2001; 19: 3415–3421
   PubMed Web of Science ®Google Scholar
• Madsen K, Rosenman M, Hui S, Breitfeld PP. Value of electronic data for model validation and refinement: bacteremia risk in children with fever and neutropenia. J Pediatr Hematol Oncol 2002; 24: 256–262
   PubMedGoogle Scholar
• Rosenman M, Madsen K, Hui S, Breitfeld PP. Modeling administrative outcomes in fever and neutropenia: clinical variables significantly influence length of stay and hospital charges. J Pediatr Hematol Oncol 2002; 24: 263–268
   PubMed Web of Science ®Google Scholar
• Weinberger M, Elattar I, Marshall D, et al. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) 1992; 71: 24–43
   PubMed Web of Science ®Google Scholar
• Storek J, Espino G, Dawson MA, Storer B, Flowers ME, Maloney DG. Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood 2000; 96: 3290–3293
   PubMed Web of Science ®Google Scholar
• Neumanitis J, Shannon-Dorcy K, Applebaum FR, et al. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony- stimulating factor. Blood 1993; 82: 1422–1427
   Google Scholar
• Neumanitis J. Use of macrophage colony-stimulating factor in the treatment of fungal infections. Clin Infect Dis 1998; 26: 1279–1281
   Google Scholar
• Leleu X, Sendid B, Fruit J, et al. Combined antifungal therapy and surgical resection as treatment of pulmonary zygomycosis in allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24: 417–420
   PubMedGoogle Scholar
• Richardson DS, Newland AC. Current perspectives on the use of growth factors in the therapy of acute myeloid leukaemia; malignancy. Hematol 2000; 5: 189–203
   PubMedGoogle Scholar
• Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989; 111: 223–321
   PubMed Web of Science ®Google Scholar
• Brambilla AM, Castagna A, Nocita B, et al. Relation between CD4 cell counts and HIV RNA levels at onset of opportunistic infections. J Acquir Immune Defic Syndr 2001; 27: 44–48
   Google Scholar
• Chiou CC, Groll AH, Mavrogiorgos N, Wood LV, Walsh TJ. Esophageal candidiasis in human immunodeficiency virus-infected pediatric patients after the introduction of highly active antiretroviral therapy. Pediatr Infect Dis J 2002; 21: 388–392
   Google Scholar
• Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84: 2221–2228
   PubMed Web of Science ®Google Scholar
• Pirsch JD, Maki DG. Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Increased susceptibility to fungal infections. Ann Intern Med 1986; 104: 619–631
   Google Scholar
• Blay JY, Chauvin F, Le Cesne A, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996; 14: 636–643
   Google Scholar
• Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 1999; 353: 1293–1298
   PubMed Web of Science ®Google Scholar
• Furrer H, Opravil M, Rossi M, et al. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study. AIDS 2001; 15: 501–507
   PubMed Web of Science ®Google Scholar
• Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999; 340: 1301–1306
   PubMed Web of Science ®Google Scholar
• Koletar SL, Heald AE, Finkelstein D, et al. A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to >200×106 /l. AIDS 2001; 15: 1509–1515
   PubMed Web of Science ®Google Scholar
• Lopez Bernaldo de Quiros JC, Miro JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA. N Engl J Med 2001; 344: 159–167
   PubMed Web of Science ®Google Scholar
• Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000; 181: 1635–1642
   PubMed Web of Science ®Google Scholar
• Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?. AIDS 1999; 13: 1647–1651
   PubMed Web of Science ®Google Scholar
• Small TN, Avigan D, Dupont B, et al. Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. Biol Blood Marrow Transplant 1997; 3: 65–75
   PubMedGoogle Scholar
• Storek J, Gooley T, Witherspoon RP, Sullivan KM, Storb R. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol 1997; 54: 131–138
   PubMed Web of Science ®Google Scholar
• van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. Medicine 1998; 77: 246–254
   PubMedGoogle Scholar
• Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274–1277
   PubMed Web of Science ®Google Scholar
• Wingard JR. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin Infect Dis 1994; 19(Suppl 1)S49–S53
   PubMed Web of Science ®Google Scholar
• Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122–1128
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002; 40: 3551–3557
   PubMed Web of Science ®Google Scholar
• Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319–1324
   PubMed Web of Science ®Google Scholar
• Balajee SA, Weaver M, Imhof A, Gribskov J, Marr KA. Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals. Antimicrob Agents Chemother 2004; 48: 1197–1203
   PubMed Web of Science ®Google Scholar
• Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24: 235–247
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764–771
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Benjamin DK, Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192–198
   PubMed Web of Science ®Google Scholar
• Safdar A, Papadopoulos EB, Young JW. Breakthrough Scedosporium apiospermum (Pseudallescheria boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high-risk allogeneic hematopoietic stem cell transplantation. Scedosporiasis and recent advances in antifungal therapy. Transpl Infect Dis 2002; 4: 212–217
   PubMedGoogle Scholar
• Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001; 135: 412–422
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225–234
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240–248
   PubMed Web of Science ®Google Scholar
• Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705–713
   PubMed Web of Science ®Google Scholar
• Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950–952
   PubMed Web of Science ®Google Scholar
• Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743–746
   PubMed Web of Science ®Google Scholar
• Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39: 584–587
   PubMed Web of Science ®Google Scholar
• Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581–1582
   PubMed Web of Science ®Google Scholar
• Kauffman CA. Zygomycosis: reemergance of an old pathogen. Clin Infect Dis 2004; 39: 588–590
   PubMed Web of Science ®Google Scholar
• Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health 2002; 5: 26–34
   PubMed Web of Science ®Google Scholar
• Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D. Primer on medical decision analysis: Part 2- Building a tree. Med Decis Making 1997; 17: 126–135
   PubMed Web of Science ®Google Scholar
• Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA. Primer on medical decision analysis: Part 1- Getting started. Med Decis Making 1997; 17: 123–125
   PubMed Web of Science ®Google Scholar
• Krahn MD, Naglie G, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 4- Analyzing the model and interpreting the results. Med Decis Making 1997; 17: 142–151
   Google Scholar
• Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 3- Estimating probabilities and utilities. Med Decis Making 1997; 17: 136–141
   PubMedGoogle Scholar